R3R01

DRUG2 trials

Sponsors

River 3 Renal Corp.

Conditions

Alport SyndromeDiabetic Kidney DiseaseFocal Segmental Glomerulosclerosis

Phase 2

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

CompletedNCT05267262

River 3 Renal Corp.Alport Syndrome, Focal Segmental Glomerulosclerosis

Start: 2022-06-15End: 2025-08-19Updated: 2025-09-29

The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.

RecruitingNCT06600412

River 3 Renal Corp.Diabetic Kidney Disease

Start: 2024-10-10End: 2027-04-01Target: 60Updated: 2026-06-29